Table 2.
Acquired point mutations in FLT3-ITD patients after FLT3 inhibitor therapy.
| Mutation | Disease | Therapy | Reference | Validated in vitro |
|---|---|---|---|---|
| N676K | AML | PKC412 | Heidel et al. (164) | 32D |
| A848P | CMML Relapsed blast crisis | Sunitinib and sorafenib | von Bubnoff et al. (165) | Ba/F3 |
| F691L | AML | AC220 | Smith et al. (161) | Ba/F3 |
| AML | AC220 | Albers et al. (167) | Ba/F3 | |
| AML (pediatric) | Sorafenib | Baker et al. (168) | ||
| D835Y | AML | AC220 | Smith et al. (161) | Ba/F3 |
| AML | Sorafenib | Man et al. (169) | ||
| AML (pediatric) | Sorafenib | Baker et al. (168) | ||
| D835V | AML | AC220 | Smith et al. (161) | |
| D835F | AML | AC220 | Smith et al. (161) | |
| D835H | AML | Sorafenib | Man et al. (169) | Ba/F3 |
| AML (pediatric) | Sorafenib | Baker et al. (168) | ||
| D651G | AML | Sorafenib | Zhang et al. (170) | |
| G619C | AML | Sorafenib | Zhang et al. (170) | |
| I687F | AML | Sorafenib | Zhang et al. (170) | |
| E858K | AML | Sorafenib | Zhang et al.(170) |